Skip to content

Double-blind, placebo-controlled study for the effect of quercetin -rich onion (Quer-gold, Sarasara-gold) on cognitive function

Double-blind, placebo-controlled study for the effect of quercetin -rich onion (Quer-gold, Sarasara-gold) on cognitive function - Effect of quercetin -rich onion on cognitive function

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000015940
Enrollment
48
Registered
2014-12-14
Start date
2015-01-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Improvement of cognitive function

Interventions

Intake 10g of quercetin -rich onion powder (50mg quercetin) daily for 24 weeks. Intake 10g of White onion powder (0mg quercetin) daily for 24 weeks.

Sponsors

Hokkaido Information University
Lead Sponsor
(1)National Food Research Institute, National Agriculture and Food Research Organization (2)Tokushima University (3)Gifu University (4)National Agriculture and Food Research Organization for Hokkaido Region (5)National Agriculture and Food Research Organization for Tohoku Region (6)Gifu farming techniques center (7)Kagoshima agriculture development synthesis center (8)Okamoto Plant Breeding Co.Ltd.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1)Subjects who show low score of Cognitive impairment rating scale (2)Subjects who agree to participate in the current study with written informed consent. (3) Subject with an study partner.

Exclusion criteria

Exclusion criteria: (1)Subjects who are under medication for dementia, Alzheimer's disease, psychiatric disorder and cerebrovascular disease. (2) Subjects with receiving hormone therapy. (3) Subjects with a history of psychiatric disorder and cerebrovascular disease. (4) Subjects with serious diseases and infections. (5) Subjects with clinical history of gastrointestinal surgery. (6)Subjects with unusually high and/or low blood pressure, or with abnormal hematological data. (7) Subjects with serious anemia. (8)Subjects with a history of allergy to medicine and food, especially onion. (9) Subjects routinely on supplementation which would affect cognitive function. (10) Heavy smokers and alcohol addicts, or subjects with irregular lifestyle. (11) Subjects who donate 400ml whole blood within 12 weeks or who donate plasma or platelets within 4 weeks prior to supplementation. (12) Subjects who are pregnant or under lactation, or ones who would be expected to be pregnant during the study. (13) Subjects who participate in other clinical trials within the last one month prior to the current clinical trial. (14) Subjects who are not eligible due to physician's judgment

Design outcomes

Primary

MeasureTime frame
Mini mental state test, Cognitive impairment rating scale

Secondary

MeasureTime frame
blood glucose, HbA1c, T-Cho, LDL-Cho, HDL-Cho, TG, oxo-LDL, estradiol, NPI-Q-J

Countries

Japan

Contacts

Public ContactDir. Prof. Jun Nishihira, M.D.

Hokkaido Information University Health Information Science Center

nishihira@do-johodai.ac.jp011-385-4430

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026